Skip to content

Study · Not a test of the peptide alone · 2025

7 results

Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.

Oe Y, Omori T, Aimono E, Furukawa S, Kitakawa H, Tateno M, Sakai K, Cho KY

Frontiers in endocrinology26 May 2025Cited by 2 (Europe PMC)

PMID40491599 (opens in a new tab)PMCIDPMC12146166 (opens in a new tab)DOI10.3389/fendo.2025.1501984 (opens in a new tab)PepBankPUB-40491599
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Metabolic dysfunction-associated steatohepatitis (MASH) has cardiometabolic risk factors, such as obesity and type 2 diabetes, and has been reported to have a potentially higher risk of mortality than conventional steatotic liver diseases. Liver fibrosis develops and can progress to cirrhosis and hepatocellular carcinoma. Although some antidiabetic agents have been reported to ameliorate the condition, no specific medical treatment has been developed to date. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) that has shown efficacy against MASH in some clinical trials. However, these trials were limited to those with mild-to-moderate fibrosis and their history of treatment was often unclear. Here, we report the case of a 50-year-old man with a 16-year history of diabetes. He demonstrated poor control of his diabetes with elevated liver enzymes. A liver biopsy was performed and he was diagnosed with steatohepatitis. Liraglutide was administered for 3 years but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023. The histological examination found cirrhosis and liraglutide was switched to tirzepatide. Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme levels improved. A third biopsy was performed, which showed a marked improvement in histology, with the amelioration of liver fibrosis. A diagnosis of steatotic liver disease was made. Although some previous studies had demonstrated an amelioration of liver fibrosis and an improvement in the prognosis of patients following GLP-1RA treatment, effective medications for patients with severe fibrosis or who are refractory to treatment with GLP-1RAs has not been identified to date. We reported a case with severe MASH whose condition had ameliorated by switching from conventional GLP-1RAs to tirzepatide.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In one man with diabetes and steatohepatitis, liver function deteriorated during the 3-year liraglutide phase of a liraglutide-then-tirzepatide sequence; no causal drug effect or numerical contrast was established.

    In plain wordsIn one man with diabetes and steatohepatitis, liver function worsened during the liraglutide phase before switching to tirzepatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiver function
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Liraglutide was administered for 3 years but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023.
    3 context sentences
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.
    Summary · context
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneCase report or seriesEfficacy outcome

    In one man with diabetes and steatohepatitis, glycemic control deteriorated during the 3-year liraglutide phase of a liraglutide-then-tirzepatide sequence; no causal drug effect or numerical contrast was established.

    In plain wordsIn one man with diabetes and steatohepatitis, glycemic control worsened during the liraglutide phase before switching to tirzepatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlycemic control
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Liraglutide was administered for 3 years but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023.
    3 context sentences
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.
    Summary · context
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In one man with diabetes and cirrhotic steatohepatitis, glycated hemoglobin improved after the liraglutide-to-tirzepatide switch over 6 months; no signed coefficient or isolated native-drug effect was established.

    In plain wordsIn one man with diabetes and cirrhotic steatohepatitis, glycated hemoglobin improved after the liraglutide-to-tirzepatide switch; no isolated drug effect was established.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedGlycated hemoglobin
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme levels improved.
    3 context sentences
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.
    Summary · context
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  4. 04HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In one man with diabetes and cirrhotic steatohepatitis, elevated liver enzyme levels improved after the liraglutide-to-tirzepatide switch over 6 months; no signed coefficient or isolated native-drug effect was established.

    In plain wordsIn one man with diabetes and cirrhotic steatohepatitis, elevated liver enzyme levels improved after the liraglutide-to-tirzepatide switch; no isolated drug effect was established.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedLiver enzyme levels
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme levels improved.
    3 context sentences
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.
    Summary · context
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In one man with diabetes and cirrhotic steatohepatitis, liver histology improved after the liraglutide-to-tirzepatide switch over 6 months; no signed coefficient or isolated native-drug effect was established.

    In plain wordsIn one man with diabetes and cirrhotic steatohepatitis, liver histology improved after the liraglutide-to-tirzepatide switch; no isolated drug effect was established.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedLiver histology
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    A third biopsy was performed, which showed a marked improvement in histology, with the amelioration of liver fibrosis.
    3 context sentences
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.
    Summary · context
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  6. 06HumanNot a test of Tirzepatide aloneCase report or seriesEfficacy outcome

    In one man with diabetes and cirrhotic steatohepatitis, liver fibrosis improved after the liraglutide-to-tirzepatide switch over 6 months; no signed coefficient or isolated native-drug effect was established.

    In plain wordsIn one man with diabetes and cirrhotic steatohepatitis, liver fibrosis improved after the liraglutide-to-tirzepatide switch; no isolated drug effect was established.

    Peptide
    Tirzepatide
    Outcome
    Direction not reportedLiver fibrosis
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    A third biopsy was performed, which showed a marked improvement in histology, with the amelioration of liver fibrosis.
    3 context sentences
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.
    Summary · context
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  7. 07HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In one man with diabetes and steatohepatitis, biopsy showed cirrhosis after the 3-year liraglutide phase and before switching to tirzepatide; this was an occurrence, not proof of drug causation.

    In plain wordsIn one man with diabetes and steatohepatitis, biopsy showed cirrhosis before the liraglutide-to-tirzepatide switch; drug causation was not established.

    Peptide
    Liraglutide
    Outcome
    Not applicableBiopsy-confirmed cirrhosis before switching to tirzepatide
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    The histological examination found cirrhosis and liraglutide was switched to tirzepatide.
    3 context sentences
    Summary · context
    Liraglutide was administered for 3 years but his liver function and glycemic control deteriorated gradually and a second liver biopsy was performed in 2023.
    Summary · context
    Here, we report the case of a 50-year-old man with a 16-year history of diabetes.
    Summary · context
    A liver biopsy was performed and he was diagnosed with steatohepatitis.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.